相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。
Correction
Clinical Neurology
Alvaro Cobo-Calvo et al.
JOURNAL OF NEUROLOGY
(2022)
Article
Clinical Neurology
Jeffrey A. Cohen et al.
Summary: For patients with multiple sclerosis using anti-CD20 therapies and S1PRMs, their IgG response to the SARS-CoV-2 vaccine is reduced, while other treatment methods can preserve IgG response.
MULTIPLE SCLEROSIS JOURNAL
(2022)
Article
Clinical Neurology
Larissa Dams et al.
Summary: This case report describes a 59-year-old man who developed myelin oligodendrocyte glycoprotein (MOG)-positive longitudinal extensive transverse myelitis (LETM) after receiving the COVID-19 vaccine ChAdOx1 nCoV-19, with therapeutic plasma exchange leading to gradual improvement in his condition.
MULTIPLE SCLEROSIS JOURNAL
(2022)
Article
Clinical Neurology
Zoya G. Georgieva et al.
Summary: Real-world investigation on ocrelizumab recipients showed that the humoral response after a single dose of COVID-19 vaccine is lower than expected in CD20-deplete patients. However, the second vaccine dose was able to convert a significant portion of non-responders to seroconverters, indicating a potential improvement in immunogenicity.
MULTIPLE SCLEROSIS JOURNAL
(2022)
Editorial Material
Clinical Neurology
Sarah Wright
MULTIPLE SCLEROSIS JOURNAL
(2022)
Article
Clinical Neurology
Edouard Januel et al.
Summary: Recent studies suggest a lower anti-spike protein-based immunoglobulin-G response following COVID-19 vaccination in patients treated with anti-CD20 and fingolimod. This study evaluated cases of COVID-19 occurring after vaccination among patients with MS and NMO, finding mild severity in cases reported. The results emphasize the need for a third COVID-19 vaccine dose for anti-CD20 treated patients and call for further prospective studies on vaccine efficacy in MS and NMO patients.
MULTIPLE SCLEROSIS JOURNAL
(2022)
Article
Clinical Neurology
Virginia Rinaldi et al.
Summary: ADEM is an inflammatory demyelinating disease of the CNS, often occurring after infections but in rare cases after vaccinations. This case report describes a patient who developed ADEM symptoms after receiving a COVID-19 vaccine, but completely recovered after corticosteroid treatment.
MULTIPLE SCLEROSIS JOURNAL
(2022)
Article
Clinical Neurology
Carla Tortorella et al.
Summary: This study evaluated the immune-specific response after full SARS-CoV-2 vaccination in patients with multiple sclerosis (MS) treated with different disease-modifying drugs. The results showed that mRNA vaccines induced both humoral and cell-mediated specific immune responses against viral spike proteins in the majority of patients with MS. These findings have important implications for promoting vaccination in all MS patients.
Article
Clinical Neurology
Afagh Garjani et al.
Summary: This study investigated the changes in SARS-CoV-2 infection risk among patients receiving disease-modifying therapies for multiple sclerosis (MS) after vaccination. The results showed that patients taking ocrelizumab or fingolimod had a lower level of protection from the SARS-CoV-2 vaccines compared to the general population.
MULTIPLE SCLEROSIS AND RELATED DISORDERS
(2022)
Article
Clinical Neurology
Ana Zabalza et al.
Summary: This study investigated the humoral and cellular responses to SARS-CoV-2 in convalescent COVID-19 patients with multiple sclerosis (PwMS) and explored factors influencing the persistence of these immune responses. The results showed that both humoral and cellular responses can persist for several months in convalescent patients, but they are influenced by treatment methods and disease characteristics.
NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION
(2022)
Article
Clinical Neurology
Emilio Portaccio et al.
Summary: The survey conducted by ECTRIMS showed the impact of COVID-19 emergency on access to care for PwMS and on MS treatment practices, with telemedicine playing a crucial role in overcoming limited access to care. Gathering data on DMT safety remains crucial for informing treatment decisions.
MULTIPLE SCLEROSIS JOURNAL
(2022)
Article
Clinical Neurology
Celine Louapre et al.
Summary: SARS-CoV-2 antibody response was reduced in patients with MS or NMO-SD treated with anti-CD20 therapies, suggesting the need for long-term monitoring of reinfection risk and specific vaccination strategies in this population.
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY
(2022)
Letter
Clinical Neurology
Paulus S. Rommer et al.
MULTIPLE SCLEROSIS JOURNAL
(2022)
Article
Clinical Neurology
Tim Spelman et al.
Summary: The study aimed to analyze the association between MS disease-modifying therapy (DMT) exposure and hospitalization in patients with COVID-19. Among the 476 reported COVID-19 cases in MS patients in the Swedish MS registry, 61.3% were confirmed cases. Of these confirmed infections, 23.2% required hospitalization, with a higher hospitalization rate observed in patients on rituximab compared to other DMTs.
MULTIPLE SCLEROSIS JOURNAL
(2022)
Article
Clinical Neurology
Maria Pia Sormani et al.
Summary: The study assessed the relationship between disease-modifying therapy (DMT) and the development of anti-SARS-CoV-2 antibodies in patients with multiple sclerosis (MS), finding that patients treated with anti-CD20 drugs had a lower likelihood of developing antibodies.
MULTIPLE SCLEROSIS JOURNAL
(2022)
Article
Clinical Neurology
Lauren Uhr et al.
Summary: The willingness to receive COVID-19 vaccines among people living with multiple sclerosis (PwMS) is relatively high, and is significantly associated with willingness to receive influenza vaccines. Factors such as older age, other race, and functional disability can influence vaccine willingness in this population.
MULTIPLE SCLEROSIS JOURNAL
(2022)
Article
Clinical Neurology
Zoe Y. G. J. van Lierop et al.
Summary: In this observational study, personalized dosing of ocrelizumab for multiple sclerosis patients during the COVID-19 pandemic showed no clinical relapses and stable serum neurofilament light levels. A minority of patients showed Expanded Disability Status Scale progression, and a small percentage exhibited radiological disease activity in MRI scans. The study suggests that personalized dosing of ocrelizumab could extend intervals with low disease activity incidence, supporting further research on its long-term safety and efficacy.
MULTIPLE SCLEROSIS JOURNAL
(2022)
Editorial Material
Clinical Neurology
Ana Zabalza et al.
MULTIPLE SCLEROSIS JOURNAL
(2022)
Article
Clinical Neurology
Steve Simpson-Yap et al.
Summary: Using data from 12 sources in 28 countries, this study examined the characteristics of COVID-19 severity in people with MS, particularly those taking immunosuppressive therapies. The results showed that older age, progressive MS phenotype, and higher disability were associated with worse COVID-19 outcomes. Additionally, rituximab was consistently associated with increased risk of hospitalization, ICU admission, and need for ventilation, while ocrelizumab was mainly associated with hospitalization and ICU admission.
Article
Clinical Neurology
Amber Salter et al.
Summary: This study examined outcomes and risk factors associated with COVID-19 clinical severity in a large, diverse cohort of North American patients with multiple sclerosis. The study found that ambulatory disability, older age, male sex, Black race, cardiovascular comorbidities, and recent corticosteroid use were associated with increased odds of worse clinical severity in MS patients with COVID-19. Knowledge of these risk factors may help improve the treatment and monitoring of these patients.
Article
Medicine, General & Internal
Maria Pia Sormani et al.
Summary: This study found that anti-CD20 treatment and fingolimod in MS patients led to reduced humoral response to mRNA vaccines. mRNA-1273 vaccine resulted in significantly higher antibody levels compared to BNT162b2, suggesting it may be preferred for patients under certain treatments.
Article
Clinical Neurology
Leoni Rolfes et al.
Summary: The study found that extending interval dosing of ocrelizumab for RRMS patients during the COVID-19 pandemic did not result in decreased effectiveness compared to standard interval dosing. Both treatment regimens were effective in maintaining clinical stability and preventing disease progression.
NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION
(2021)
Review
Clinical Neurology
Rosa E. Boeschoten et al.
JOURNAL OF THE NEUROLOGICAL SCIENCES
(2017)
